Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

COPANLISIB for Diffuse large b-cell lymphoma recurrent: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 10 adverse event reports in the FDA FAERS database where COPANLISIB was used for Diffuse large b-cell lymphoma recurrent.

Most Reported Side Effects for COPANLISIB

Side Effect Reports % Deaths Hosp.
Pyrexia 58 16.3% 10 53
Off label use 43 12.1% 1 20
Hyperglycaemia 27 7.6% 2 18
Hypertension 24 6.8% 1 12
Rash maculo-papular 24 6.8% 4 16
Pneumonia 20 5.6% 6 15
Sepsis 19 5.4% 8 12
Diarrhoea 18 5.1% 2 5
Rash 16 4.5% 3 10
Febrile neutropenia 15 4.2% 6 8
Neutropenia 15 4.2% 3 5
Neutropenic sepsis 15 4.2% 2 14
Anaemia 14 3.9% 4 12
Dyspnoea 14 3.9% 6 12
Cytopenia 13 3.7% 0 11

Other Indications for COPANLISIB

Follicular lymphoma (42) B-cell lymphoma (38) Marginal zone lymphoma (29) Product used for unknown indication (23) Non-hodgkin's lymphoma recurrent (20) Diffuse large b-cell lymphoma (17) Non-hodgkin's lymphoma (11) B-cell lymphoma recurrent (10) Non-hodgkin's lymphoma unspecified histology indolent (6) Colorectal cancer (5)

Other Drugs Used for Diffuse large b-cell lymphoma recurrent

RITUXIMAB (507) ETOPOSIDE (174) BENDAMUSTINE (168) CYTARABINE (165) DEXAMETHASONE (162) CYCLOPHOSPHAMIDE (144) CISPLATIN (137) AXICABTAGENE CILOLEUCEL (123) TISAGENLECLEUCEL (118) GEMCITABINE (117)

Related Pages

COPANLISIB Full Profile All Diffuse large b-cell lymphoma recurrent Drugs COPANLISIB Demographics COPANLISIB Timeline